Merck Plans Phase III Prevymis CMV Trials In Renal Transplant Patients

 
• By Sten Stovall
  
CMV
Merck Hopes To Use First-Mover CMV Advantage In Kidney Transplant Patients • Source: Shutterstock

More from Anti-infective

More from Therapy Areas